Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN  
660.63
+3.48 (+0.53%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)73.01B
Current PE9.20
Forward PE 14.99
2yr Forward PE 14.81
See more stats
Estimates Current Quarter
Revenue$2.82 Billion
Adjusted EPS$10.18
See more estimates
10-Day MA$652.03
50-Day MA$678.76
200-Day MA$637.33
See more pivots

Regeneron Pharmaceuticals, Inc. Stock, NASDAQ:REGN

777 Old Saw Mill River Road, Tarrytown, New York 10591-6707
United States of America
Phone: +1.914.847.7000
Number of Employees: 10368

Description

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.